BR Biopharma, Inc. (NASDAQ:BRBI) Short Interest Update

Key Points

• Short interest fell 65.4% to 1,225 shares as of August 31, representing approximately 0.0% of shares outstanding and 1.2 days of average trading volume.
• BR Biopharma shares opened at $11.22, with a $132.5 million market capitalization, a 140.26 price-to-earnings ratio, and a 52-week range of $9.09 to $67.01.
• Analyst sentiment remained negative, with Weiss Ratings reaffirming a “sell (D-)” rating and the stock carrying an average “Sell” rating; the company’s annualized dividend yield was 5.0%, but its payout ratio was an unusually high 525%.

BR Biopharma, Inc. (NASDAQ:BRBI - Get Free Report) saw a large decline in short interest during the month of August. As of August 31st, there was short interest totaling 1,225 shares, a decline of 65.4% from the August 15th total of 3,543 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average daily volume of 1,065 shares, the short-interest ratio is presently 1.2 days.

BR Biopharma Stock Performance

NASDAQ:BRBI opened at $11.22 on Friday. BR Biopharma has a one year low of $9.09 and a one year high of $67.01. The firm's fifty day moving average is $10.82 and its two-hundred day moving average is $12.76. The firm has a market cap of $132.52 million and a price-to-earnings ratio of 140.26.

BR Biopharma (NASDAQ:BRBI - Get Free Report) last posted its quarterly earnings results on Tuesday, June 30th. The company reported $0.09 EPS for the quarter. The business had revenue of $25.13 million during the quarter.

BR Biopharma Cuts Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 4th. Investors of record on Monday, August 17th were paid a $0.1415 dividend. This represents a $0.57 dividend on an annualized basis and a yield of 5.0%. The ex-dividend date of this dividend was Monday, August 17th. BR Biopharma's dividend payout ratio is presently 525.00%.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of BR Biopharma in a research report on Tuesday, September 1st. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has an average rating of "Sell".

Hedge Funds Weigh In On BR Biopharma

A hedge fund recently bought a new stake in BR Biopharma stock. Acuitas Investments LLC purchased a new stake in BR Biopharma, Inc. (NASDAQ:BRBI - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 3,000 shares of the company's stock, valued at approximately $45,000. BR Biopharma comprises 3.2% of Acuitas Investments LLC's investment portfolio, making the stock its 7th biggest position.

BR Biopharma Company Profile

BRBI BR Partners SA, through its subsidiaries, operates as an investment bank which specializes in providing financial services for entrepreneurs and families principally in Brazil. It offers financial advisory services for mergers and acquisitions, capital markets, board services, shareholders, special situations and restructuring, pre-IPO, and privatization; and wealth management services. BRBI BR Partners SA is based in S?o Paulo, Brazil.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.